RT Journal Article
SR Electronic
T1 SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.02.11.430787
DO 10.1101/2021.02.11.430787
A1 Markus Hoffmann
A1 Prerna Arora
A1 Rüdiger Groß
A1 Alina Seidel
A1 Bojan Hörnich
A1 Alexander Hahn
A1 Nadine Krüger
A1 Luise Graichen
A1 Heike Hofmann-Winkler
A1 Amy Kempf
A1 Martin Sebastian Winkler
A1 Sebastian Schulz
A1 Hans-Martin Jäck
A1 Bernd Jahrsdörfer
A1 Hubert Schrezenmeier
A1 Martin Müller
A1 Alexander Kleger
A1 Jan Münch
A1 Stefan Pöhlmann
YR 2021
UL http://biorxiv.org/content/early/2021/02/11/2021.02.11.430787.abstract
AB The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa) and B.1.1.248 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of UK, South Africa and Brazil variant into human cells is susceptible to blockade by entry inhibitors. In contrast, entry of the South Africa and Brazil variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment and was less efficiently inhibited by serum/plasma from convalescent or BNT162b2 vaccinated individuals. These results suggest that SARS-CoV-2 may escape antibody responses, which has important implications for efforts to contain the pandemic.Competing Interest StatementThe authors have declared no competing interest.